文献速递眼底病与葡萄膜炎

美国IRIS注册研究中接受抗VEGF治疗的新生血管性年龄相关性黄斑变性患者的失访情况

Loss to Follow-up in Patients with Neovascular Age-Related Macular Degeneration Treated with Anti-VEGF Therapy in the United States in the IRIS® Registry.
PubMed 文献 · Ophthalmology · 2023-02-28

结果显示11.6%的患者失访(定义为末次注射后12个月内无随访),14.3%的患者不持续(定义为末次注射后6个月内无随访)。高龄、男性、单眼受累、糖尿病、医疗补助保险及种族或族裔是失访和不持续的风险因素。

要点

  • 11.6%的患者在末次抗VEGF注射后12个月内失访,14.3%在6个月内不持续。
  • 81至84岁患者失访风险最高(OR 2.51,95%CI 2.31-2.74),不持续风险也最高(OR 2.13,95%CI 1.98-2.29)。
  • 黑人或非裔美国患者、医疗补助保险者失访风险较高,联邦医疗保险按服务付费者失访风险较低。

核心结论

  • 近1/9接受抗VEGF注射治疗的新生血管性AMD患者失访,1/7患者不持续。
  • 识别出的风险因素包括年龄增加、男性、单眼受累、糖尿病、医疗补助保险以及种族或族裔。

研究设计与样本

  • 回顾性队列研究,使用IRIS注册数据。
  • 采用多变量逻辑回归模型估计比值比(OR)和95%置信区间(CI)。

主要发现

  • 11.6%的患者(95%CI 11.4%-11.7%)失访,88.4%的患者在12个月内随访。
  • 14.3%的患者(95%CI 14.1%-14.4%)不持续,85.7%的患者在6个月内随访。
  • 与70岁及以下患者相比,81至84岁患者失访的OR为2.51(95%CI 2.31-2.74,P<0.001),不持续的OR为2.13(95%CI 1.98-2.29,P<0.001)。
  • 与白人患者相比,黑人或非裔美国患者失访的OR为1.32(95%CI 1.08-1.61,P=0.007),不持续的OR为1.38(95%CI 1.15-1.65,P<0.001);西班牙裔患者不持续的OR为1.13(95%CI 1.03-1.24,P=0.009)。
  • 与私人保险相比,医疗补助保险者失访的OR为1.27(95%CI 1.01-1.60,P=0.04),联邦医疗保险按服务付费者失访的OR为0.69(95%CI 0.64-0.74,P<0.001)。

关键数值与推荐

  • 失访定义为末次玻璃体腔内注射后12个月内无随访。
  • 不持续定义为末次玻璃体腔内注射后6个月内无随访。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the incidence of being lost to follow-up (LTFU) and nonpersistence in patients with neovascular age-related macular degeneration (AMD) treated with anti-VEGF injections in the United States. DESIGN: Retrospective cohort study using the IRIS® (Intelligent Research in Sight) Registry data. PARTICIPANTS: One hundred fifty-six thousand three hundred twenty-seven treatment-naive patients with neovascular AMD who subsequently were treated with anti-VEGF therapy from 2013 through 2015 and followed up through 2019. METHODS: Multivariable logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). MAIN OUTCOME MEASURES: Being LTFU was defined as no follow-up within 12 months from last intravitreal injection. Nonpersistence was defined as no follow-up within 6 months from last intravitreal injection. RESULTS: For neovascular AMD, 11.6% of patients (95% CI, 11.4%-11.7%) were LTFU, and 88.4% of patients were followed up within 12 months. The rate of being LTFU generally was higher with increasing age, with odds of being LTFU greatest for patients between 81 and 84 years of age (OR, 2.51; 95% CI, 2.31-2.74; P < 0.001) compared with patients 70 years of age and younger. Odds of being LTFU for Black or African American patients (OR, 1.32; 95% CI, 1.08-1.61; P = 0.007) were greater than for White patients. Odds of being LTFU were higher for patients with Medicaid insurance (OR, 1.27; 95% CI, 1.01-1.60; P = 0.04) and lower for patients with Medicare Fee-For-Service insurance (OR, 0.69; 95% CI, 0.64-0.74; P < 0.001) than for patients with private insurance. Furthermore, 14.3% (95% CI, 14.1-14.4) of patients were nonpersistent, and 85.7% of patients underwent follow-up within 6 months. Odds of nonpersistence also were greatest among patients between 81 and 84 years of age (OR, 2.13; 95% CI, 1.98-2.29; P < 0.001) compared with patients 70 years of age or younger. Odds of nonpersistence for Black or African-American patients (OR, 1.38; 95% CI, 1.15-1.65; P < 0.001) and Hispanic patients (OR, 1.13; 95% CI, 1.03-1.24; P = 0.009) were greater than odds for White patients. CONCLUSIONS: Nearly 1 of 9 patients with neovascular AMD treated with anti-VEGF injections became LTFU, whereas 1 of 7 patients were nonpersistent. Risk factors identified included increasing age, male sex, unilateral involvement, diabetes, Medicaid insurance, and race or ethnicity. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Khurana RN, Li C, Lum F, et al. Loss to Follow-up in Patients with Neovascular Age-Related Macular Degeneration Treated with Anti-VEGF Therapy in the United States in the IRIS® Registry. Ophthalmology. 2023. PMID: 36858288. doi:10.1016/j.ophtha.2023.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。